` MYX (Mayne Pharma Group Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

MYX
vs
S&P/ASX 300

Over the past 12 months, MYX has outperformed S&P/ASX 300, delivering a return of 19% compared to the S&P/ASX 300's 6% growth.

Stocks Performance
MYX vs S&P/ASX 300

Loading
MYX
S&P/ASX 300
Add Stock

Performance Gap
MYX vs S&P/ASX 300

Loading
MYX
S&P/ASX 300
Difference

Performance By Year
MYX vs S&P/ASX 300

Loading
MYX
S&P/ASX 300
Add Stock

Competitors Performance
Mayne Pharma Group Ltd vs Peers

S&P/ASX 300
MYX
LLY
JNJ
NOVO B
ROG
Add Stock

Mayne Pharma Group Ltd
Glance View

Market Cap
526.5m AUD
Industry
Pharmaceuticals

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

MYX Intrinsic Value
8.18 AUD
Undervaluation 21%
Intrinsic Value
Price
Back to Top